AMAG Pharmaceuticals: AdCom Votes 9 to 7 to Remove Makena from the Market, but I Don’t Think It Will Happen: AMAG (AMAG, $9.80), Antares Pharma (ATRS, $3.40, Buy)Wednesday, October 30, 2019 · 8:44 am |
|
Antares (ATRS, Buy, $3.51); AMAG Pharmaceuticals (AMAG, $11.73) First Thoughts about How the PROLONG Study Could Affect Makena UsageMonday, March 11, 2019 · 11:04 am |
|
AMAG Pharmaceuticals: Trying to Project 2019 Sales for the Makena Franchise (AMAG, $24.45, Buy)Friday, August 17, 2018 · 9:32 am |
|
AMAG Pharmaceuticals: Strong Launch of Subcu Makena and Pending Sale of Cord Blood Registry is Encouraging (AMAG, $23.55, Buy)Friday, June 15, 2018 · 11:44 am |
|
AMAG: It Is Early Days, but the Launch of the Subcutaneous Dosage Form of Makena Seems to be Going Very Well (AMAG, Buy, $21.17)Monday, May 7, 2018 · 11:44 am |
|
AMAG: Upgrading to Buy Based on an In-Depth Analysis of the Outlook for Makena Over the 2018 to 2020 Period (AMAG, Buy, $21.10))Friday, April 13, 2018 · 5:20 pm |
|
AMAG Pharmaceuticals: Will FDA Approve Makena SC (AMAG, Neutral, $21.75)Friday, February 3, 2017 · 10:15 am |
|
AMAG and Antares: Update on the Development of Makena SC (AMAG, Neutral, $24.40) (ATRS, Buy, $2.04)Thursday, January 26, 2017 · 9:44 am |
|
AMAG Pharmaceuticals: Initiation of Research on a Complex but Potentially Very Interesting Investment Situation (AMAG, Neutral, $24)Sunday, June 26, 2016 · 9:11 am |
|
|
There are 9 reports on file. |
